HDAC8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28250	0.57	14/20
SCHEMBL29476	0.57	14/20
SCHEMBL31064	0.57	14/20
SCHEMBL30259	0.57	14/20
Vorinostat (SCHEMBL9018)	1.00	13/20
SCHEMBL28328	0.61	13/20
SCHEMBL28329	0.61	13/20
SCHEMBL28330	0.61	13/20
SCHEMBL29695	0.61	13/20
SCHEMBL30199	0.61	13/20
SCHEMBL19539	0.48	13/20
SCHEMBL21138	0.55	12/20
SCHEMBL21139	0.55	12/20
SCHEMBL21140	0.55	12/20
SCHEMBL30622	0.55	12/20
SCHEMBL34229	0.51	11/20
Trichostatin (SCHEMBL19886)	1.00	10/20
SCHEMBL28840	0.61	9/20
SCHEMBL28841	0.61	9/20
SCHEMBL28842	0.61	9/20

Clinical trials — most relevant to HDAC8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Voronistat in Pediatric Patients With Drug Resistant Epilepsy	PHASE2	UNKNOWN
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma	PHASE2	RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.	PHASE2	COMPLETED
Clinical Trial of SAHA in Patients With Breast Cancer	PHASE1/PHASE2	UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Research In Viral Eradication of HIV Reservoirs	PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors	PHASE1	COMPLETED
SHP-141C in Plaque Type Psoriasis	PHASE1	COMPLETED
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma	PHASE1	COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction	PHASE1	COMPLETED
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer	EARLY_PHASE1	WITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	nan	WITHDRAWN
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HDAC8 binder may also engage these)

Protein	Name	Similarity
B1WC68	—	1.000	B1WC68 →
Q0VCB2	—	1.000	Q0VCB2 →
Q8VH37	—	1.000	Q8VH37 →
B1H369	—	0.983	B1H369 →
Q6GPA7	—	0.981	Q6GPA7 →
Q9NVE7	—	0.951	Q9NVE7 →
Q4R4U1	—	0.951	Q4R4U1 →
Q5R5F8	—	0.951	Q5R5F8 →
P51583	—	0.949	P51583 →
Q9DCL9	—	0.948	Q9DCL9 →
Q5NVN7	—	0.947	Q5NVN7 →
P38024	—	0.946	P38024 →
Q4ZHR9	—	0.943	Q4ZHR9 →
Q923S8	—	0.943	Q923S8 →
SAE1	SUMO-activating enzyme subunit 1	0.943	landscape →
Q5VU57	—	0.943	Q5VU57 →
P20595	—	0.942	P20595 →
Q8BWB6	—	0.942	Q8BWB6 →
GUCY1B1	Guanylate cyclase soluble subunit beta-1 (GCS	0.942	landscape →
P52848	—	0.942	P52848 →
A2VE14	—	0.941	A2VE14 →
Q02353	—	0.941	Q02353 →
Q6AXQ0	—	0.941	Q6AXQ0 →
Q5RB59	—	0.941	Q5RB59 →
A7YWS7	—	0.940	A7YWS7 →
Q9H1A3	—	0.940	Q9H1A3 →
Q9CQC8	—	0.939	Q9CQC8 →
Q9NZD8	—	0.938	Q9NZD8 →
O54865	—	0.938	O54865 →
Q5ZKQ6	—	0.938	Q5ZKQ6 →